Lumexa outlines $235M-$241M 2026 adjusted EBITDA amid Hospital for Special Surgery joint venture expansion
We haven't written up this one. Seeking Alpha News has the full story — the link below goes straight to it.
More in Health & Medicine
From petri dish to patient:biotech’s formidable obstacle course
Bulls N’ Bears follows a biotech breakthrough from the laboratory to the patient and examines how Australian companies are negotiating the hurdles along the way.
From petri dish to patient:biotech’s formidable obstacle course
Bulls N’ Bears follows a biotech breakthrough from the laboratory to the patient and examines how Australian companies are negotiating the hurdles along the way.
SHC orders formation of committee to probe HIV outbreak among children at Karachi hospital
KARACHI: The Sindh High Court (SHC) directed the provincial government on Thursday to constitute a committee for an “independent, impartial and comprehensive” inquiry into the HIV outbreak among…
Chinese yeast factory boosts cancer drug production speed 1,000 times
A research team at Zhejiang University has cracked a molecular puzzle, turning ordinary yeast into a powerful factory for an expensive cancer drug and boosting its production by a thousand times.
How Tamil Nadu invested in sustained awareness and building trust to shape its organ donation programme
About 72% of deceased organ donations in the country happens in five States - Tamil Nadu, Telangana, Maharashtra, Gujarat and Karnataka.
Celltrion Secures FDA Fast Track Designation for All Three Clinical-Stage ADC Candidates
Celltrion said on Aug. 13 that its antibody-drug conjugate (ADC) candidate CT-P73 has received Fast Track designation from the U.S.